Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 2008International Journal of Laboratory HematologyOpen Access

A rapid flow cytometric technique for the detection of platelet‐monocyte complexes, activated platelets and platelet‐derived microparticles

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does a rapid flow cytometric technique reliably measure changes in platelet activation in patients undergoing PCI compared to healthy controls?

Population

20 healthy controls and 20 patients undergoing percutaneous coronary intervention (PCI)

Comparison

Percutaneous coronary intervention with… vs Pre-PCI baseline and healthy controls

Design

Cohort

Follow-up

Pre- and post-PCI

Authors

LPLaura PearsonOur Lady's HospitalJTJim ThomWinnMedMAMJ AdamsMurdoch University

Discussion

Loading...

Member takes

Implication

Rapid flow cytometry may track platelet activation changes around PCI; leaves open clinical utility for risk stratification or therapy guidance.

Key Points

  • To optimize and evaluate a rapid flow cytometric assay for detecting activated platelets, platelet-monocyte complexes, and platelet-derived microparticles in healthy and clinical cohorts.
  • Optimized pre- and post-analytical flow cytometry conditions and established baseline reference ranges in 20 healthy control participants.
  • Assessed activated platelets, platelet-monocyte complexes, soluble CD40 ligand, soluble P-selectin, and plasma phospholipids in 20 patients before and after percutaneous coronary intervention (PCI).
  • Activated platelets (P = 0.005) and platelet-monocyte complexes (P = 0.0275) were significantly higher in pre-PCI patients compared to healthy controls.
  • Post-PCI testing demonstrated significant reductions in activated platelets (P = 0.0027), soluble CD40 ligand (P = 0.0066), soluble P-selectin (P < 0.0001), and plasma phospholipids (P = 0.0032), reflecting antiplatelet therapy.

Structured PICO

Does a rapid flow cytometric technique reliably measure changes in platelet activation in patients undergoing PCI compared to healthy controls?

P
Population
20 healthy controls and 20 patients undergoing percutaneous coronary intervention (PCI)
I
Intervention
Percutaneous coronary intervention (PCI) with concurrent antiplatelet therapy
C
Comparator
Pre-PCI baseline and healthy controls
O
Outcome
Platelet activation measured by flow cytometry (platelet-derived microparticles, activated platelets, platelet-monocyte complexes) and soluble markers (sCD40 ligand, sP-selectin, plasma phospholipids)surrogate

A rapid flow cytometric technique reliably detects ex vivo platelet activation and reflects changes in activation status following PCI and antiplatelet therapy.

Cite This Study

Pearson et al. (2008) studied this question.

synapsesocial.com/papers/6a89cf5781d3bfa98ef7df79https://doi.org/10.1111/j.1751-553x.2008.01059.x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Platelet degranulation and monocyte–platelet complex formation are increased in the acute and convalescent phases after ischaemic stroke or transient ischaemic attack2004 · 132 citations
  2. 2Preanalytical requirements for flow cytometric evaluation of platelet activation: choice of anticoagulant1999 · 71 citations
  3. 3Application of Flow Cytometry to Platelet Disorders2004 · 120 citations
  4. 4Platelet-derived microvesicles and activated platelets express factor Xa activity1995 · 59 citations
  5. 5The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease2003 · 73 citations